Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia

Table 3

HBV DNA during treatment and followup, per-protocol data.

	Roma		Non-Roma
M6 HBV DNA <2000 IU/mL	26/39	66.7%	37/44	84.1%	0.06
M6 HBV DNA negative	3/39	7.7%	7/44	15.9%	0.172
M12 HBV DNA <2000 IU/mL	22/32	68.8%	37/46	80.4%	0.237
M12 HBV DNA negative	3/32	9.4%	9/46	19.6%	0.220
M18 HBV DNA <2000 IU/mL	13/29	44.8%	19/34	55.9%	0.382
M18 HBV DNA negative	0/29	0%	3/34	8.8%	0.167

M6: 6 months after the start of the treatment, M12: end of treatment, and M18: 6 months after the end of the treatment.